JP2010539508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539508A5 JP2010539508A5 JP2010525420A JP2010525420A JP2010539508A5 JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5 JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5
- Authority
- JP
- Japan
- Prior art keywords
- ccr4
- pamphlet
- tumor
- activity
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0718167.0 | 2007-09-18 | ||
| GB0718167A GB0718167D0 (en) | 2007-09-18 | 2007-09-18 | Cancer marker and therapeutic target |
| PCT/GB2008/003160 WO2009037454A2 (en) | 2007-09-18 | 2008-09-18 | Cancer marker and therapeutic target |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015131752A Division JP6234967B2 (ja) | 2007-09-18 | 2015-06-30 | 癌マーカーおよび治療ターゲット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539508A JP2010539508A (ja) | 2010-12-16 |
| JP2010539508A5 true JP2010539508A5 (enExample) | 2012-10-04 |
| JP5774309B2 JP5774309B2 (ja) | 2015-09-09 |
Family
ID=38670078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525420A Expired - Fee Related JP5774309B2 (ja) | 2007-09-18 | 2008-09-18 | 癌マーカーおよび治療ターゲット |
| JP2015131752A Expired - Fee Related JP6234967B2 (ja) | 2007-09-18 | 2015-06-30 | 癌マーカーおよび治療ターゲット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015131752A Expired - Fee Related JP6234967B2 (ja) | 2007-09-18 | 2015-06-30 | 癌マーカーおよび治療ターゲット |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9134293B2 (enExample) |
| EP (3) | EP2535716B1 (enExample) |
| JP (2) | JP5774309B2 (enExample) |
| AU (1) | AU2008300413B2 (enExample) |
| CA (1) | CA2699702C (enExample) |
| DK (3) | DK2533047T3 (enExample) |
| ES (3) | ES2443541T3 (enExample) |
| GB (1) | GB0718167D0 (enExample) |
| PL (3) | PL2535716T3 (enExample) |
| RU (2) | RU2529797C2 (enExample) |
| WO (1) | WO2009037454A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0623815Y2 (ja) | 1988-10-06 | 1994-06-22 | 株式会社大金製作所 | エア回転継手のシール装置 |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| US11029313B2 (en) | 2008-09-26 | 2021-06-08 | The General Hospital Corporation | Method of treating cervical neoplasia in patients infected with human papilloma virus |
| WO2010037042A2 (en) | 2008-09-26 | 2010-04-01 | The General Hospital Corporation | Methods for detecting and treating cancer |
| GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| EP2580348B1 (en) * | 2010-06-14 | 2018-04-25 | Qiagen GmbH | Method for determination of target cells or tissue for extraction of biomolecules from non-formalin-fixed biological samples |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
| HK1212389A1 (en) | 2011-10-24 | 2016-06-10 | Signalchem Lifesciences Corporation | Carbonic anhydrase ix-related markers and use thereof |
| JP6141864B2 (ja) | 2011-12-01 | 2017-06-07 | ケモセントリックス，インコーポレイティド | Ｃｃｒ（４）アンタゴニストとしての置換アニリン |
| GB2512857A (en) * | 2013-04-09 | 2014-10-15 | Cancer Res Technology | Cancer biomarker |
| PL3065774T3 (pl) * | 2013-11-06 | 2021-12-13 | Janssen Biotech, Inc | Przeciwciała anty-ccl17 |
| DK3148579T3 (da) | 2014-05-28 | 2021-03-08 | Agenus Inc | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf |
| WO2016050904A1 (en) * | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject |
| AU2016248222A1 (en) * | 2015-04-17 | 2017-11-09 | Eisai, Inc. | Methods for treating lung cancer |
| EP3329244B1 (en) | 2015-07-30 | 2022-10-05 | Qiagen GmbH | Method of preparing a frozen biological sample |
| SG10201912984WA (en) | 2015-12-02 | 2020-03-30 | Agenus Inc | Antibodies and methods of use thereof |
| JP7177445B2 (ja) * | 2017-05-19 | 2022-11-24 | 真吾 前田 | Ｃｃｒ４阻害による制御性ｔ細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法 |
| ES3064498T3 (enExample) | 2018-08-29 | 2026-04-27 | Chemocentryx Inc | |
| EP3885452A1 (en) * | 2020-03-23 | 2021-09-29 | Koninklijke Philips N.V. | Prediction of radiotherapy response for prostate cancer subject based on chemokine genes |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786158A (en) * | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| WO1994021814A1 (en) * | 1993-03-19 | 1994-09-29 | The Johns Hopkins University | Antibodies and assays for determining mutations in the apc gene |
| GB9501683D0 (en) | 1995-01-27 | 1995-03-15 | Glaxo Group Ltd | Substances and their uses |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US6488930B1 (en) | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| US6245332B1 (en) | 1999-01-15 | 2001-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of systemic memory T cell trafficking |
| WO2001064754A1 (en) | 2000-03-03 | 2001-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Gene recombinant antibody and its fragment |
| WO2002030357A2 (en) | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| US20020173524A1 (en) | 2000-10-11 | 2002-11-21 | Tularik Inc. | Modulation of CCR4 function |
| AU2002223619B2 (en) | 2000-10-18 | 2006-08-24 | Schering Ag | Use of antiprogestins for the induction of apoptosis in a cell |
| MXPA03007681A (es) * | 2001-02-28 | 2004-11-12 | Protein Design Labs Inc | Receptores para quimiocinas y enfermedades. |
| WO2002094264A1 (en) | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| CA2456928A1 (en) | 2001-08-10 | 2003-02-20 | Topigen Pharmaceutique Inc. | Cellular virus receptors and methods of use |
| MXPA04001894A (es) | 2001-08-31 | 2005-09-08 | Kyowa Hakko Kogyo Kk | Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo. |
| AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
| WO2004045526A2 (en) | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| JP2007524362A (ja) * | 2003-02-14 | 2007-08-30 | サイグレス ディスカバリー， インコーポレイテッド | 癌における治療ｇｐｃｒ標的 |
| US7807389B2 (en) * | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| SE0301650D0 (sv) | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
| SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| US7732442B2 (en) | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
| EP1688436A4 (en) * | 2003-10-08 | 2009-12-02 | Kyowa Hakko Kirin Co Ltd | ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY |
| DE602004029934D1 (de) | 2003-12-04 | 2010-12-16 | Kyowa Hakko Kirin Co Ltd | Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| JP2007217282A (ja) | 2004-03-04 | 2007-08-30 | Astellas Pharma Inc | 置換ピリミジン誘導体 |
| WO2005106471A2 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4) |
| JP2007269629A (ja) | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
| RU2296328C1 (ru) * | 2005-09-21 | 2007-03-27 | Общество с ограниченной ответственностью "ГЕН" | Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| EP1984501B1 (en) | 2006-02-14 | 2011-05-18 | Noxxon Pharma AG | Mcp-i binding nucleic acids |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
-
2007
- 2007-09-18 GB GB0718167A patent/GB0718167D0/en not_active Ceased
-
2008
- 2008-09-18 JP JP2010525420A patent/JP5774309B2/ja not_active Expired - Fee Related
- 2008-09-18 WO PCT/GB2008/003160 patent/WO2009037454A2/en not_active Ceased
- 2008-09-18 EP EP12183760.3A patent/EP2535716B1/en not_active Not-in-force
- 2008-09-18 PL PL12183760T patent/PL2535716T3/pl unknown
- 2008-09-18 EP EP08806315.1A patent/EP2176664B1/en not_active Not-in-force
- 2008-09-18 PL PL08806315T patent/PL2176664T3/pl unknown
- 2008-09-18 AU AU2008300413A patent/AU2008300413B2/en not_active Ceased
- 2008-09-18 ES ES08806315.1T patent/ES2443541T3/es active Active
- 2008-09-18 RU RU2010123921/15A patent/RU2529797C2/ru not_active IP Right Cessation
- 2008-09-18 US US12/679,002 patent/US9134293B2/en not_active Expired - Fee Related
- 2008-09-18 ES ES12183760.3T patent/ES2612690T3/es active Active
- 2008-09-18 EP EP12182790.1A patent/EP2533047B1/en not_active Not-in-force
- 2008-09-18 PL PL12182790.1T patent/PL2533047T3/pl unknown
- 2008-09-18 DK DK12182790.1T patent/DK2533047T3/en active
- 2008-09-18 CA CA2699702A patent/CA2699702C/en not_active Expired - Fee Related
- 2008-09-18 ES ES12182790.1T patent/ES2588507T3/es active Active
- 2008-09-18 DK DK12183760.3T patent/DK2535716T3/en active
- 2008-09-18 DK DK08806315.1T patent/DK2176664T3/da active
-
2014
- 2014-07-14 RU RU2014128513A patent/RU2014128513A/ru not_active Application Discontinuation
-
2015
- 2015-06-30 JP JP2015131752A patent/JP6234967B2/ja not_active Expired - Fee Related
- 2015-08-11 US US14/823,755 patent/US10261099B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010123921A (ru) | Раковый маркер и терапевтическая мишень | |
| Zubair et al. | Advanced approaches to breast cancer classification and diagnosis | |
| Huang et al. | Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation | |
| Tanaka et al. | Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma | |
| JP2012085556A (ja) | 乳がんの診断方法 | |
| JP2017184729A5 (enExample) | ||
| TWI776816B (zh) | 一種偵測和/或篩檢患者之結腸直腸癌、結腸直腸腺瘤、或息肉以及評估患者結腸鏡檢查之適當性之方法 | |
| Han et al. | Expression of PTEN and mTOR in pancreatic neuroendocrine tumors | |
| JP2009511524A (ja) | ケモカイン発現のｅｇｆｒ依存調節ならびに腫瘍とその副作用の治療及び診断に与えるケモカイン発現調節の影響 | |
| Hou et al. | Detecting ALK-rearrangement of CTC enriched by nanovelcro chip in advanced NSCLC patients | |
| Ikuta et al. | The current management of clear cell sarcoma | |
| JP2008514209A5 (enExample) | ||
| Liu et al. | Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer | |
| Wang et al. | Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma | |
| Sandri et al. | Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma | |
| Obata et al. | Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer | |
| CN116559462A (zh) | 用于肿瘤患者预后的生物标志物组及其用途 | |
| JP7369378B2 (ja) | 抗がん剤及びがんを治療するための医薬組成物 | |
| JP2012085554A (ja) | 乳がんのサブタイプの判別方法 | |
| JP2012085555A (ja) | 乳がん診断用マーカー | |
| He et al. | Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma | |
| JP6466911B2 (ja) | Ｃｃｌ２２及びｃｃｌ１７癌生物マーカー | |
| JP2008535491A5 (enExample) | ||
| JPWO2007099852A1 (ja) | 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット | |
| US20250290155A1 (en) | Clinical workflow for treatment of breast cancer |